Search

(GlobeNewswire) - Correction: All information was not included in previous pressrelease. PRESS RELEASE, Lund Sweden, November 24, 2020 - Active Biotech (NASDAQ STOCKHOLM: ACTI) Active Biotech AB (publ) (ticker: ACTI) [...]

Contract notice: Medicinal products containing ixazomib, Alectinib, Lenvatinib, Venetoclax Name of the active substance, strength and size of the package: Ixazomib citrate 4 MG CPS DUR 3 (3X1), ATC: L01XX50, [...]

Takeda, a global values-based, R&D-driven biopharmaceutical company, is returning to the China International Import Expo (CIIE) this year to showcase its innovative medicines and breakthrough therapies, and to demonstrate its [...]

The in-class transition to oral ixazomib-lenalidomide-dexamethasone appears feasible in randomized clinical trial ineligible patients with multiple myeloma (MM) in US community oncology centers despite the range of comorbidities, according to [...]

Takeda Pharmaceutical has reported results from the Phase III TOURMALINE-MM2 clinical trial of Ninlaro (ixazomib) plus lenalidomide and dexamethasone to treat multiple myeloma. The combination was compared to lenalidomide and [...]

(GlobeNewswire) - Lund Sweden, August 3, 2020 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that the first patient has been dosed in the phase 1b/2a clinical study of tasquinimod [...]

Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that the first patient has been dosed in the phase 1b/2a clinical study of tasquinimod for treatment of relapsed or refractory multiple myeloma. [...]

Contract awarded for Ixazomib 4mg Date of conclusion of the contract: 25-05-2020 Contract price: 7. 781,00 Deadline: 20 days Place of execution - Country, District, Municipality: Portugal, porto, porto Contractor [...]

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) today announced it will orally present the results of two studies at the 25th Congress of the European Hematology Association (EHA). Presentations are available [...]

(GlobeNewswire) - Lund, June 3, 2020 - Active Biotech (Nasdaq Stockholm: ACTI) today provides a status update in the projects following the new direction communicated in early February. This abbreviated [...]

(GlobeNewswire) - Lund, June 3, 2020 - Active Biotech (Nasdaq Stockholm: ACTI) today provides a status update in the projects following the new direction communicated in early February. This abbreviated [...]

A combination of Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone failed to significantly extend the time to disease progression or death in people with newly diagnosed multiple myeloma who are ineligible [...]

Takeda Pharmaceutical Company Limited (Takeda) announced the results from the TOURMALINE-MM2 study designed to evaluate the addition of NINLARO (ixazomib) to lenalidomide and dexamethasone in newly diagnosed transplant ineligible multiple [...]

Takedas Ninlaro (ixazomib) has fallen short in a late-stage study testing it in combination with Bristol-Myers Squibb/Celgenes Revlimid and chemo in newly diagnosed multiple myeloma. The data from the TOURMALINE-MM2 [...]

Takeda Pharmaceutical said that the phase 3 TOURMALINE-MM2 study evaluating the addition of NINLARO (ixazomib) to lenalidomide and dexamethasone in certain multiple myeloma population could not deliver the desired results. [...]

Takeda Pharmaceutical Company has reported that its oral multiple myeloma drug Ninlaro (ixazomib) missed the progression-free survival (PFS) endpoint in the TOURMALINE-MM2 study. The study was designed to evaluate the [...]

Takeda has unveiled new Phase 3 data for its oral proteasome inhibitor Ninlaro (ixazomib) in the treatment of newly diagnosed transplant ineligible multiple myeloma, revealing that the therapy, when combined [...]

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced the results from the TOURMALINE-MM2 study designed to evaluate the addition of NINLARO (ixazomib) to lenalidomide and dexamethasone in newly [...]

A company that last year won accelerated Food and Drug Administration approval for a drug to treat multiple myeloma patients who have received numerous prior therapies will seek to expand [...]

Contract awarded for 191g004039 - ixazomib 4 mg caps Date of conclusion of the contract: 13-11-2019 Contract price: 15. 561,96 Deadline: 48 days Place of execution - Country, District, Municipality: [...]

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting [...]

Contract awarded for Ixazomib 4 mg caps Date of conclusion of the contract: 27-11-2019 Contract price: 15. 561,96 Deadline: 32 days Place of execution - Country, District, Municipality: Portugal, autonomous [...]

Takeda Pharmaceutical Company Limited ('Takeda') announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The trial evaluated the effect of single-agent oral NINLARO [...]

Tenders are invited for delivery of the drug (inn: ixazomib) Given in the technical specifications Document Purchase Start date : 11 Jul 2019 Major organization : STATE PUBLIC INSTITUTION 'MANAGEMENT [...]

Cambridge, June 6 -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) today announced that the Phase 3 TOURMALINE-AL1 clinical trial in patients with relapsed or refractory systemic light-chain (AL) amyloidosis [...]

Takeda Pharmaceutical Company Limited announced that the company will present data at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31-June 4 in Chicago and [...]

Contract notice: conclusion of non-exclusive discount agreements according to 130a abs. 8 sgb v to those in ii.2.4. mentioned active substances with completion option in the context of the so-called [...]